Immune-related adverse events from immune checkpoint inhibitors in pediatric patients: A literature review and case series
-
Published:2023-12
Issue:
Volume:2
Page:100117
-
ISSN:2772-610X
-
Container-title:EJC Paediatric Oncology
-
language:en
-
Short-container-title:EJC Paediatric Oncology
Author:
Cupit-Link MargaretORCID,
Khan RajaORCID,
Pappo AlbertoORCID,
Helmig Sara
Reference28 articles.
1. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors;Hargadon;Int Immunopharmacol.,2018
2. Fundamental mechanisms of immune checkpoint blockade therapyFundamental mechanisms of immune checkpoint blockade therapy;Wei;Cancer Discov.,2018
3. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance;Martins;Nat. Rev. Clin. Oncol.,2019
4. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study;Geoerger;Lancet Oncol.,2020
5. Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial;Loeb;Cancer Immunol. Immunother.,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献